Active, not recruitingPhase 2NCT06093841
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Principal Investigator
- Weili Zhao, PhDRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- Intervention
- Relmacabtagene Autoleucel(biological)
- Enrollment
- 46 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (13)
- Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
- Shandong Cancer Hospital, Jinan, Shandong, China
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,, Shanghai, Shanghai Municipality, China
- Institute of Hematology&Hospital of Blood Disease CAMS, Tianjin, Tianjin Municipality, China
- Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
- The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Beijing Tongren Hospital, Beijing, China
- Peking Union Medical College Hospital, Beijing, China
- Jiangsu Provincial People's Hospital, Nanjing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06093841 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic